EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Multicenter surveillance of antifungal susceptibility of clinical Aspergillus isolates to conventional and novel antifungal agents in Taiwan, 2021–2023

Ming-I Hsieh iD, Pui-Ching Choi iD, Wan-Lin Wu iD, Yu-Fu Lin iD, Chi-Jung Wu iD

Microbiology Spectrum · 2026

DOI: 10.1128/spectrum.02659-25 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Microbiology Spectrum, 2026. Verfasst von Ming-I Hsieh und 4 weiteren Autor:innen. Beteiligte Einrichtung: National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Tainan, Taiwan. Hauptthemen laut MEDLINE: Antifungal Agents, Aspergillus, Aspergillosis. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taiwan Centers for Disease Control, National Health Research Institutes.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Periodic surveillance of antifungal susceptibility among Aspergillus isolates is essential to guide effective treatment. This multicenter study analyzed 550 clinical Aspergillus isolates collected in Taiwan from 2021 to 2023, primarily from the respiratory tract (69.6%) and ear (12.9%). Calmodulin-based sequencing identified 24 species across six Aspergillus sections: Flavi (28.7%), Fumigati (28.5%), Nigri (21.6%), Terrei (15.8%), Nidulantes (5.1%), and Circumdati (0.2%). The major sections were represented by Aspergillus fumigatus (99.4%), Aspergillus flavus (91.8%), and Aspergillus terreus (100%), while section Nigri comprised nine species, with Aspergillus welwitschiae (57.1%) predominant. Using Clinical Laboratory Standards Institute (CLSI) M38-A3 protocols, reduced susceptibility to amphotericin B (MIC > 1 µg/mL) was observed in A. flavus (8.3%), A. terreus (22.7%), and section Nidulantes (32.1%). Acquired voriconazole resistance was found in 5.8% (9/156) of A. fumigatus isolates, including eight with cyp51A mutations (3 TR 34 /L98H, 4 TR 34 /L98H/S297T/F495I, and 1 TR 46 /Y121F/T289A). Voriconazole non-wild-type phenotypes were identified in 2.1% (3/158) of A. flavus isolates, including one carrying a novel P214L mutation (orthologous to A. fumigatus P216L). Members of the Aspergillus niger clade exhibited reduced susceptibility to itraconazole and isavuconazole. Anidulafungin, along with novel antifungals including orolofim, manogepix, and rezafungin, demonstrated broad activity across Aspergillus species, including those with intrinsic or acquired azole resistance. Ibrexafungerp also showed efficacy against azole-resistant A. fumigatus and A. flavus . In contrast, opelconazole exhibited limited activity against A. flavus , the A. niger clade, Aspergillus sydowii , and voriconazole-resistant A. fumigatus . These findings underscore the need for species-level identification, susceptibility testing of causative isolates, and continued surveillance to detect emerging resistance and support the use of novel non-azole antifungals for azole-resistant aspergillosis. IMPORTANCE Timely and effective antifungal therapy is essential for aspergillosis. This multicenter surveillance study provides comprehensive insights into the species distribution and antifungal susceptibility of 550 clinical Aspergillus isolates in Taiwan, with intrinsic reduced susceptibility to amphotericin B, itraconazole, or isavuconazole noted in certain species. Regarding acquired resistance, a novel cyp51A mutation, P214L, was identified in an azole-resistant Aspergillus flavus , orthologous to Aspergillus fumigatus P216L. Recovery of azole-resistant A. fumigatus harboring TR34/L98H or TR46/Y121F/T289A mutations remains a concern and emphasizes the need for antifungal stewardship in the environment. Novel antifungals, including orolofim, manogepix, rezafungin, and ibrexafungerp, demonstrated broad activity across Aspergillus species, including resistant isolates. Nevertheless, the inhaled agent opelconazole exhibited limited activity against A. flavus regardless of voriconazole susceptibility and against other species showing reduced susceptibility to itraconazole. These findings highlight the importance of species-level identification, susceptibility testing, and continued surveillance and support the use of novel antifungals for aspergillosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antifungal AgentsAspergillusAspergillosisTaiwanMicrobial Sensitivity TestsHumansDrug Resistance, FungalFungal ProteinsPyridinesAmphotericin BItraconazoleVoriconazoleTriazolesPyrrolesPiperazinesNitrilesAcetamidesPyrimidines

Stichwörter der Autor:innen

AspergillusTaiwanamphotericin Bantifungal resistanceazoleechinocandinibrexafungerpmanogepixorolofimrezafungin

Substanzen

Antifungal AgentsisavuconazoleolorofimFungal ProteinsPyridinesAmphotericin BItraconazoleVoriconazoleTriazolesPyrroles

Autor:innen und Institutionen

  • National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Tainan, Taiwan.
  • Division of Infectious Diseases, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University, Tainan, Taiwan.

ORCID-Profile: Ming-I Hsieh, Pui-Ching Choi, Wan-Lin Wu, Yu-Fu Lin, Chi-Jung Wu

Förderung

  • Taiwan Centers for Disease Control
  • National Health Research Institutes

Zitieren

APA

Hsieh, M., Choi, P. C., Wu, W. L., Lin, Y. F., & Wu, C. J. (2026). Multicenter surveillance of antifungal susceptibility of clinical Aspergillus isolates to conventional and novel antifungal agents in Taiwan, 2021–2023. Microbiology Spectrum. https://doi.org/10.1128/spectrum.02659-25

Vancouver

Hsieh M, Choi PC, Wu WL, Lin YF, Wu CJ. Multicenter surveillance of antifungal susceptibility of clinical Aspergillus isolates to conventional and novel antifungal agents in Taiwan, 2021–2023. Microbiology Spectrum. 2026. doi:10.1128/spectrum.02659-25

BibTeX
@article{Hsieh2026,
  author = {Hsieh, Ming-I and Choi, Pui-Ching and Wu, Wan-Lin and Lin, Yu-Fu and Wu, Chi-Jung},
  title = {Multicenter surveillance of antifungal susceptibility of clinical Aspergillus isolates to conventional and novel antifungal agents in Taiwan, 2021–2023},
  journal = {Microbiology Spectrum},
  year = {2026},
  doi = {10.1128/spectrum.02659-25}
}
Kostenlos starten →